42860-17-3

Basic information

• Product Name: 4-chloro-3-iodobenzoyl chloride
• Synonyms: 4-chloro-3-iodobenzoyl chloride
• CAS NO: 42860-17-3
• Molecular Formula: C₇H₃Cl₂IO
• Molecular Weight: 301
• Mol File: 42860-17-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 308.1±27.0 °C(Predicted)
• Appearance: /
• Density: 2.007±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-chloro-3-iodobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-3-iodobenzoyl chloride(42860-17-3)
• EPA Substance Registry System: 4-chloro-3-iodobenzoyl chloride(42860-17-3)

Safety Data

• Hazardous Substances Data: 42860-17-3(Hazardous Substances Data)

Upstream product

• 42860-04-8 4-chloro-3-iodobenzoic acid 
• 2840-28-0 3-amino-4-chloro-benzoic acid 

Downstream Products

• 834895-51-1 3-iodo-4-pyrrolidinobenzophenone 
• 834895-56-6 1-(3-iodo-4-pyrrolidinophenyl)-1-phenylprop-2-yn-1-ol 
• 834895-42-0 3-(3-iodo-4-pyrrolidinophenyl)-3-phenyl-3H-naphtho[2,1-b]pyran 
• 1036376-99-4 4-chloro-3-iodo-N-[3-(trifluoromethyl)phenyl]benzamide 
• 1049809-51-9 3-(4-chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]-pyridine-5-carboxylic acid tert-butyl ester 
• 1048674-88-9 3-(4-chloro-3-iodo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine 
• 1049809-42-8 C₁₇H₂₀ClIN₂O₄S 
• 1350438-42-4 C₈H₄ClIN₂O 
• 1350438-47-9 C₁₅H₈Cl₂IN₃ 
• 1350438-48-0 C₁₆H₉ClIN₅O 
• 1350438-49-1 C₂₃H₁₂Cl₂F₃IN₆O 
• 1350438-50-4 C₂₃H₁₂ClF₃I₂N₆O 
• 1350454-70-4 [3H]BMS-725519 
• 1350438-43-5 C₈H₅BrClIO 

Relevant articles and documents

Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors

FGF receptors (FGFRs) are tyrosine kinases that are overexpressed in diverse tumors by genetic alterations such as gene amplifications, somatic mutations and translocations. Owing to this characteristic, FGFRs are attractive targets for cancer treatment. It has been demonstrated that most multi-targeted, ATP competitive tyrosine kinase inhibitors are active against FGFRs as well as other kinases. The design of new and more selective inhibitors of FGFRs, which might be reduced off-target and side effects, is a difficult yet significant challenge. The results of the current investigation, show that novel Ponatinib analogues are highly active as FGFR inhibitors and that they possess reduced kinase insert domain receptor (KDR) activities. Observations made in a structure and activity relationship (SAR) investigation led to the development of a promising, orally available lead compound 4, which displays a 50–100 fold in vitro selectivity for inhibition of FGFR1-3 over KDR. In addition, biological evaluation of compound 4 showed that it displays significant antitumor activities in FGFR1-amplificated H1581 and FGFR2-amplificated SNU-16 xenograft models.

Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies

Obesity remains a significant public health issue leading to Type II diabetes and cardiovascular disease. CB1 antagonists have been shown to suppress appetite and reduce body weight in animal models as well as in humans. Evaluation of pre-clinical CB1 antagonists to establish relationships between in vitro affinity and in vivo efficacy parameters are enhanced by ex vivo receptor occupancy data. Synthesis and biological evaluation of a novel and highly selective radiolabeled CB1 antagonist is described. The radioligand was used to conduct ex vivo receptor occupancy studies.

CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.